In the validation sample set, NeXT Dx identified pathogenic BRCA2 germline variants in colorectal and head and neck cancer cases; these tumor types would typically not be referred for germline testing in the absence of other personal and family history risk factors (per guidelines), and tumor-only assays are unable to establish the origin of detected variants. The gene discussed is BRCA2; the disease is head and neck cancer.